Opticyte’s Post

Oxygen *is* medicine. Join us in recognizing #WorldOxygenDay. Good oxygen levels to the heart, lung and all vital organs are critical to our health. At Opticyte we are dedicated to delivering the technology to accurately measure that oxygen is getting to your cells and organs, regardless of skin color. Our noninvasive cellular oxygenation measurement has received the FDA’s coveted breakthrough device designation. This first of its kind, technology enabled, AI-derived measurement will help to save lives and reduce organ failure in #sepsis, #trauma, #respiratory failure, and #heart failure. Thank you to the World Health Organization for highlighting oxygen's crucial role in global health on #WorldOxygenDay.

🌟 Join us as we dig deep into new data at the Optica MedTech Industry Summit in Montreal in October! Our CEO and Founder Lori Arakaki will be sharing powerful insights on how Opticyte's Cell O2 technology is set to help transform patient care for #sepsis, #anemia, and #vasoplegia. Don't miss this opportunity to connect with innovators and clinicians in the healthcare optics space! 🌟

At Opticyte we’re not just working fast to develop the technology to help clinicians recognize sepsis early and help save lives, we’re also helping ensure we’re all aware of the dangers of sepsis and empower people to become Sepsis Superheroes through the Sepsis Alliance. We can all help. Right now one in three U.S. adults have never heard of the condition that affects an estimated 49 million people worldwide each year and is the leading cause of death in U.S. hospitals. Research shows as many as 80% of sepsis deaths could be prevented with rapid diagnosis and treatment. Become a Sepsis Superhero this September to help people recognize the signs and symptoms of sepsis to protect themselves and their loved ones. https://lnkd.in/exQPWuuq #SepsisAwareness

Join us during September as we focus on fighting the leading cause of death in US hospitals, during Sepsis Awareness Month. Together we can tackle this global threat. We’re sharing critical resources to help educate and advocate for change from the status quo from the Sepsis Alliance, the Global Sepsis Alliance and the Washington State Hospital Association to help educate others to recognize the signs and prevent infections that can lead to sepsis. Join Opticyte as we work fast to develop new technology to help clinicians recognize sepsis early and help save lives by empowering yourself and others through awareness to help stop sepsis. #SepsisAwarenessMonth #GetAheadOfSepsis #TogetherAgainstSepsis

Health equity champions, listen up and get ready to comment! The FDA's new discussion paper, "Health Equity For Medical Devices" is sparking conversations and helping build important momentum for change. We’re overdue to consider how we build clinical trial designs that prioritize diversity and inclusivity. Key points from the paper we’re reacting to: • How do demographics, socioeconomic status, and healthcare access impact disease prevalence and severity? • Are outcome disparities among patient populations device-related? • Could limited diversity in trials lead to the FDA requiring labeling that a device has demonstrated it is safe and effective for specific populations? These questions are crucial as we work towards more equitable medical devices like our VitalO₂ device. Take a deeper dive, you can find the full discussion paper and provide comments on the FDA's website. #HealthEquity #MedicalDevices #ClinicalTrials #Diversity

When a serious medical condition is recognized, it can be treated.  At Opticyte, our mission is to illuminate illness that is unseen. Sepsis is the leading cause of death in U.S. hospitals. It’s an unfortunate truth that you or someone you know has likely been impacted by sepsis. Early sepsis detection is one of the most critical unmet needs in medicine today. Pulse oximeters were developed nearly a half century ago, and they misdiagnose Black patients with dire conditions such as COVID-19, pneumonia, and COPD nearly 3x more often than White patients. Inaccuracies in today’s pulse oximeters result in delayed treatment and increased mortality rates.   At Opticyte, we are  harnessing our proprietary VitalO2 technology which is proven – in our latest study – to provide accurate readings to help quickly detect sepsis across different skin tones. Explore how you can join our journey and how Opticyte is stepping up to fight sepsis and improve health equity for hospital patients of color. 

Our CEO Lori Arakaki shares new research and her perspective on the urgent need for health equity in the pulse oximetry space. Discover how outdated technology has impacted patient outcomes, particularly in communities of color, and learn about the innovative solutions we are developing to address these disparities. Join us in our mission to create a healthier future for all. #HealthEquity #PulseOximetry #Innovation

As September approaches, we're gearing up for Sepsis Awareness Month. However, at Opticyte, our focus on detecting sepsis in people of all skin tones isn't limited to just one month - it's our mission every single day. Sepsis is a life-threatening condition affecting nearly 50 million people globally each year. Our dedicated team is working hard to develop an innovative solution that can help save lives across diverse populations. Our leading-edge technology aims to overcome the challenges in detecting sepsis early, which can be particularly difficult in individuals with darker skin tones. To see our progress and learn more about how we're planning to help tackle this global health crisis, check out our video. Don't forget to follow our page for updates as we continue to advance our mission of improving sepsis detection and treatment for everyone, everywhere. Together, we can make a difference in the fight against sepsis. #SepsisAwareness #HealthcareInnovation #MedTech  https://lnkd.in/gvZGGrp2

We're excited for Lori Arakaki to be a featured speaker at the Optica #MedTech Industry Summit this fall. It's an honor and fantastic opportunity to engage with other stakeholders for optics-based medical devices. Lori will be sharing details of our VitalO₂ monitor for noninvasive blood and cellular oxygenation measurement. Learn more about the conference here: https://lnkd.in/gxU3csuk

An observational study conducted by the University of Washington and Swedish has been using Opticyte’s VitalO₂ monitor to collect data during cardiac surgery and recovery. The study has now completed enrollment with data on 60 patients! 🌟   The study was designed to see if Cell O₂ can help predict and identify vasoplegia, a dangerous form of shock that can occur during or after cardio-pulmonary bypass.  A huge THANK YOU to all the study staff, clinical teams, and patient volunteers for their support of this research.